GlaxoSmithKline PLC Director/PDMR Shareholding (4011Q)
18 Febrero 2019 - 10:14AM
UK Regulatory
TIDMGSK
RNS Number : 4011Q
GlaxoSmithKline PLC
18 February 2019
GlaxoSmithKline plc (the 'Company')
Shares sold to meet tax liabilities
Following the vesting of awards granted in 2016 under the
GlaxoSmithKline 2009 Performance Share Plan on 14 February 2019 and
as notified on 15 February 2019, the notifications that follow
reflect changes in the interests of Persons Discharging Managerial
Responsibilities ('PDMRs') in Ordinary Shares and in American
Depositary Shares ('ADSs') of the Company arising from the sale of
Ordinary Shares or ADSs to meet tax liabilities.
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================
a) Name Ms E Walmsley
=== ======================== ============================================
b) Position/status Chief Executive Officer
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities for the vesting of awards
granted in 2016 under the Company's 2009
Performance Share Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) GBP15.8462 66,159
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2019-02-15
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== =====================================================================
a) Name Mr R G Connor
=== ======================== ===========================================
b) Position/status President, Global Vaccines
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities for the vesting of awards
granted in 2016 under the Company's 2009
Performance Share Plan.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) GBP15.8462 38,633
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-02-15
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them
('PCA')
=====================================================================
a) Name Mr J Ford
=== ======================== ===========================================
b) Position/status SVP & General Counsel
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of GlaxoSmithKline plc American Depositary
the financial Shares ('ADSs')
instrument ISIN: US37733W1053
=== ======================== ===========================================
b) Nature of the The sale of ADSs to meet tax liabilities
transaction for the vesting of awards granted in 2016
under the Company's 2009 Performance Share
Plan.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$41.1716 2,311
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-02-15
=== ======================== ===========================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them
('PCA')
=====================================================================
a) Name Mr N Hirons
=== ======================== ===========================================
b) Position/status SVP, Global Ethics & Compliance
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities for the vesting of awards
granted in 2016 under the Company's 2009
Performance Share Plan.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) GBP15.8462 15,937
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-02-15
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them
('PCA')
=======================================================================
a) Name Mr B McNamara
=== ======================== =============================================
b) Position/status CEO, Consumer Healthcare
=== ======================== =============================================
c) Initial notification/ Initial notification
amendment
=== ======================== =============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================
a) Name GlaxoSmithKline plc
=== ======================== =============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================
a) Description of GlaxoSmithKline plc American Depositary
the financial Shares ('ADSs')
instrument ISIN: US37733W1053
=== ======================== =============================================
b) Nature of the The sale of ADSs to meet tax liabilities
transaction further to the vesting of awards granted
in 2016 under the Company's 2009 Performance
Share Plan.
=== ======================== =============================================
c) Price(s) and Price(s) Volume(s)
volume(s) $41.1716 16,675
----------
=== ======================== =============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =============================================
e) Date of the transaction 2019-02-15
=== ======================== =============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================== =============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== =====================================================================
a) Name Mr D S Redfern
=== ======================== ===========================================
b) Position/status Chief Strategy Officer
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities for the vesting of awards
granted in 2016 under the Company's 2009
Performance Share Plan.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) GBP15.8462 28,009
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-02-15
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them
('PCA')
=========================================================================
a) Name Mr R Simard
=== ======================== ===============================================
b) Position/status President, Pharma Supply Chain
=== ======================== ===============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of Ordinary Shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===============================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities for the vesting of awards granted
in 2016 under the Company's 2009 Performance
Share Plan.
=== ======================== ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.8462 3,873
----------
=== ======================== ===============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===============================================
e) Date of the transaction 2019-02-15
=== ======================== ===============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== =====================================================================
a) Name Ms C Thomas
=== ======================== ===========================================
b) Position/status SVP, Human Resources
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities for the vesting of awards
granted in 2016 under the Company's 2009
Performance Share Plan.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) GBP15.8462 35,253
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-02-15
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them
('PCA')
=== =====================================================================
a) Name Mr P C Thomson
=== ======================== ===========================================
b) Position/status President, Global Affairs
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities for the vesting of awards
granted in 2016 under the Company's 2009
Performance Share Plan.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) GBP15.8462 20,283
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-02-15
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them
('PCA')
=== =====================================================================
a) Name Mrs V A Whyte
=== ======================== ===========================================
b) Position/status Company Secretary
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities for the vesting of awards
granted in 2016 under the Company's 2009
Performance Share Plan.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) GBP15.8462 3,873
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-02-15
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHQVLFFKLFFBBB
(END) Dow Jones Newswires
February 18, 2019 11:14 ET (16:14 GMT)
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
